Literature DB >> 10561194

Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology.

C E Desch1, A B Benson, T J Smith, P J Flynn, C Krause, C L Loprinzi, B D Minsky, N J Petrelli, D G Pfister, M R Somerfield.   

Abstract

OBJECTIVE: To determine the most effective, evidence-based, postoperative surveillance strategy for the detection of recurrent colon and rectal cancer. Tests are to be recommended only if they have an impact on the outcomes listed below. POTENTIAL INTERVENTION: All tests described in the literature for postoperative monitoring were considered. In addition, the data were critically evaluated to determine the optimal frequency of monitoring. OUTCOMES: Outcomes of interest included overall and disease-free survival, quality of life, toxicity reduction, and cost-effectiveness. The American Society of Clinical Oncology (ASCO) Colorectal Cancer Surveillance Expert Panel was guided by the principle of cost minimization, ie, when two strategies were believed to be equally effective, the least expensive test was recommended. EVIDENCE: A complete MEDLINE search was performed of the past 20 years of the medical literature. Keywords included colorectal cancer, follow-up, and carcinoembryonic antigen, as well as the names of the specific tests. The search was broadened by articles from the tumor marker ASCO panel literature search, as well as from bibliographies of selected articles. VALUES: Levels of evidence and guideline grades were rated by a standard process. More weight was given to studies that tested a hypothesis directly relating testing to one of the primary outcomes in a randomized design. BENEFITS/HARMS/COSTS: The possible consequences of false-positive and false-negative tests were considered in evaluating a preference for one of two tests that provide similar information. Cost alone was not a determining factor. RECOMMENDATIONS: The expert panel's recommended postoperative monitoring schema is discussed in this article. VALIDATION: Five outside reviewers, the ASCO Health Services Research Committee, and the ASCO Board of Directors examined this document. SPONSOR: American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  1999        PMID: 10561194     DOI: 10.1200/JCO.1999.17.4.1312

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  25 in total

1.  Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer.

Authors:  Ulrich Guller; Paul Zajac; Annelies Schnider; Beatrix Bösch; Stefan Vorburger; Markus Zuber; Giulio Cesare Spagnoli; Daniel Oertli; Robert Maurer; Urs Metzger; Felix Harder; Michael Heberer; Walter Richard Marti
Journal:  Ann Surg       Date:  2002-12       Impact factor: 12.969

2.  The essence of the Japan Radiological Society/Japanese College of Radiology Imaging Guideline.

Authors:  Yasuyuki Yamashita; Sadayuki Murayama; Masahiro Okada; Yoshiyuki Watanabe; Masako Kataoka; Yasushi Kaji; Keiko Imamura; Yasuo Takehara; Hiromitsu Hayashi; Kazuko Ohno; Kazuo Awai; Toshinori Hirai; Kazuyuki Kojima; Shuji Sakai; Naofumi Matsunaga; Takamichi Murakami; Kengo Yoshimitsu; Toshifumi Gabata; Kenji Matsuzaki; Eriko Tohno; Yasuhiro Kawahara; Takeo Nakayama; Shuichi Monzawa; Satoru Takahashi
Journal:  Jpn J Radiol       Date:  2016-01       Impact factor: 2.374

Review 3.  [Clinical results of digital mammography].

Authors:  R Schulz-Wendtland; K-P Hermann; W Bautz
Journal:  Radiologe       Date:  2005-03       Impact factor: 0.635

4.  Trends in follow-up and preventive care for colorectal cancer survivors.

Authors:  Claire F Snyder; Craig C Earle; Robert J Herbert; Bridget A Neville; Amanda L Blackford; Kevin D Frick
Journal:  J Gen Intern Med       Date:  2008-01-16       Impact factor: 5.128

5.  The impact of primary care physicians on follow-up care of underserved breast cancer survivors.

Authors:  Rose C Maly; Yihang Liu; Allison L Diamant; Amardeep Thind
Journal:  J Am Board Fam Med       Date:  2013 Nov-Dec       Impact factor: 2.657

6.  Population-based longitudinal study of follow-up care for patients with colorectal cancer in Nova Scotia.

Authors:  Robin Urquhart; Amy Folkes; Geoffrey Porter; Cynthia Kendell; Martha Cox; Ron Dewar; Eva Grunfeld
Journal:  J Oncol Pract       Date:  2012-07       Impact factor: 3.840

7.  Life After Cancer.

Authors:  M P Jaiprakash
Journal:  Med J Armed Forces India       Date:  2011-07-21

8.  Colon Cancer Staging in Vulnerable Older Adults: Adherence to National Guidelines and Impact on Survival.

Authors:  T B Leal; T Holden; L Cavalcante; G O Allen; J R Schumacher; M A Smith; J M Weiss; H B Neuman; N K LoConte
Journal:  Ann Hematol Oncol       Date:  2014

9.  Follow-up recommendations for colon cancer.

Authors:  W Donald Buie; Jo-Anne P Attard
Journal:  Clin Colon Rectal Surg       Date:  2005-08

10.  A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.

Authors:  Dong Hoe Koo; Jae Lyun Lee; Tae Won Kim; Heung Moon Chang; Min Hee Ryu; Sung Sook Lee; Min Kyoung Kim; Sun Jin Sym; Jung Shin Lee; Yoon Koo Kang
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.